Bill Text: OH HB501 | 2013-2014 | 130th General Assembly | Introduced
Bill Title: To add the drug Zohydro to the list of Schedule I controlled substances.
Spectrum: Partisan Bill (Republican 2-0)
Status: (Introduced - Dead) 2014-03-20 - To Health and Aging [HB501 Detail]
Download: Ohio-2013-HB501-Introduced.html
|
|
Representatives Smith, Sprague
| To amend section 3719.41 of the Revised Code to add | 1 |
| the drug Zohydro to the list of Schedule I | 2 |
| controlled substances. | 3 |
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:
| Section 1. That section 3719.41 of the Revised Code be | 4 |
| amended to read as follows: | 5 |
| Sec. 3719.41. Controlled substance schedules I, II, III, IV, | 6 |
| and V are hereby established, which schedules include the | 7 |
| following, subject to amendment pursuant to section 3719.43 or | 8 |
| 3719.44 of the Revised Code. | 9 |
| 10 | |
| (A) Narcotics-opiates | 11 |
| Any of the following opiates, including their isomers, | 12 |
| esters, ethers, salts, and salts of isomers, esters, and ethers, | 13 |
| unless specifically excepted under federal drug abuse control | 14 |
| laws, whenever the existence of these isomers, esters, ethers, and | 15 |
| salts is possible within the specific chemical designation: | 16 |
| (1) Acetyl-alpha-methylfentanyl | 17 |
| (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide); | 18 |
| (2) Acetylmethadol; | 19 |
| (3) Allylprodine; | 20 |
| (4) Alphacetylmethadol (except levo-alphacetylmethadol, also | 21 |
| known as levo-alpha-acetylmethadol, levomethadyl acetate, or | 22 |
| LAAM); | 23 |
| (5) Alphameprodine; | 24 |
| (6) Alphamethadol; | 25 |
| (7) Alpha-methylfentanyl | 26 |
| (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; | 27 |
| 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine); | 28 |
| (8) Alpha-methylthiofentanyl | 29 |
| (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- | 30 |
| phenylpropanamide); | 31 |
| (9) Benzethidine; | 32 |
| (10) Betacetylmethadol; | 33 |
| (11) Beta-hydroxyfentanyl | 34 |
| (N-[1-(2-hydroxy-2-phenethyl-4-piperidinyl]-N- phenylpropanamide); | 35 |
| (12) Beta-hydroxy-3-methylfentanyl (other name: | 36 |
| N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N- | 37 |
| phenylpropanamide); | 38 |
| (13) Betameprodine; | 39 |
| (14) Betamethadol; | 40 |
| (15) Betaprodine; | 41 |
| (16) Clonitazene; | 42 |
| (17) Dextromoramide; | 43 |
| (18) Diampromide; | 44 |
| (19) Diethylthiambutene; | 45 |
| (20) Difenoxin; | 46 |
| (21) Dimenoxadol; | 47 |
| (22) Dimepheptanol; | 48 |
| (23) Dimethylthiambutene; | 49 |
| (24) Dioxaphetyl butyrate; | 50 |
| (25) Dipipanone; | 51 |
| (26) Ethylmethylthiambutene; | 52 |
| (27) Etonitazene; | 53 |
| (28) Etoxeridine; | 54 |
| (29) Furethidine; | 55 |
| (30) Hydroxypethidine; | 56 |
| (31) Ketobemidone; | 57 |
| (32) Levomoramide; | 58 |
| (33) Levophenacylmorphan; | 59 |
| (34) 3-methylfentanyl | 60 |
| (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N- phenylpropanamide); | 61 |
| (35) 3-methylthiofentanyl | 62 |
| (N-[3-methyl-1-[2-(thienyl)ethyl]-4-piperidinyl]-N- | 63 |
| phenylpropanamide); | 64 |
| (36) Morpheridine; | 65 |
| (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); | 66 |
| (38) Noracymethadol; | 67 |
| (39) Norlevorphanol; | 68 |
| (40) Normethadone; | 69 |
| (41) Norpipanone; | 70 |
| (42) Para-fluorofentanyl | 71 |
| (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide; | 72 |
| (43) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine; | 73 |
| (44) Phenadoxone; | 74 |
| (45) Phenampromide; | 75 |
| (46) Phenomorphan; | 76 |
| (47) Phenoperidine; | 77 |
| (48) Piritramide; | 78 |
| (49) Proheptazine; | 79 |
| (50) Properidine; | 80 |
| (51) Propiram; | 81 |
| (52) Racemoramide; | 82 |
| (53) Thiofentanyl | 83 |
| (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide; | 84 |
| (54) Tilidine; | 85 |
| (55) Trimeperidine; | 86 |
| (56) Zohydro. | 87 |
| (B) Narcotics-opium derivatives | 88 |
| Any of the following opium derivatives, including their | 89 |
| salts, isomers, and salts of isomers, unless specifically excepted | 90 |
| under federal drug abuse control laws, whenever the existence of | 91 |
| these salts, isomers, and salts of isomers is possible within the | 92 |
| specific chemical designation: | 93 |
| (1) Acetorphine; | 94 |
| (2) Acetyldihydrocodeine; | 95 |
| (3) Benzylmorphine; | 96 |
| (4) Codeine methylbromide; | 97 |
| (5) Codeine-n-oxide; | 98 |
| (6) Cyprenorphine; | 99 |
| (7) Desomorphine; | 100 |
| (8) Dihydromorphine; | 101 |
| (9) Drotebanol; | 102 |
| (10) Etorphine (except hydrochloride salt); | 103 |
| (11) Heroin; | 104 |
| (12) Hydromorphinol; | 105 |
| (13) Methyldesorphine; | 106 |
| (14) Methyldihydromorphine; | 107 |
| (15) Morphine methylbromide; | 108 |
| (16) Morphine methylsulfonate; | 109 |
| (17) Morphine-n-oxide; | 110 |
| (18) Myrophine; | 111 |
| (19) Nicocodeine; | 112 |
| (20) Nicomorphine; | 113 |
| (21) Normorphine; | 114 |
| (22) Pholcodine; | 115 |
| (23) Thebacon. | 116 |
| (C) Hallucinogens | 117 |
| Any material, compound, mixture, or preparation that contains | 118 |
| any quantity of the following hallucinogenic substances, including | 119 |
| their salts, isomers, and salts of isomers, unless specifically | 120 |
| excepted under federal drug abuse control laws, whenever the | 121 |
| existence of these salts, isomers, and salts of isomers is | 122 |
| possible within the specific chemical designation. For the | 123 |
| purposes of this division only, "isomer" includes the optical | 124 |
| isomers, position isomers, and geometric isomers. | 125 |
| (1) Alpha-ethyltryptamine (some trade or other names: | 126 |
| etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; | 127 |
| 3-(2-aminobutyl) indole; alpha-ET; and AET); | 128 |
| (2) 4-bromo-2,5-dimethoxyamphetamine (some trade or other | 129 |
| names: 4-bromo-2,5-dimethoxy-alpha-methyphenethylamine; | 130 |
| 4-bromo-2,5-DMA); | 131 |
| (3) 4-bromo-2,5-dimethoxyphenethylamine (some trade or other | 132 |
| names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; | 133 |
| alpha-desmethyl DOB; 2C-B, Nexus); | 134 |
| (4) 2,5-dimethoxyamphetamine (some trade or other names: | 135 |
| 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 136 |
| (5) 2,5-dimethoxy-4-ethylamphetamine (some trade or other | 137 |
| names: DOET); | 138 |
| (6) 4-methoxyamphetamine (some trade or other names: | 139 |
| 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; | 140 |
| PMA); | 141 |
| (7) 5-methoxy-3,4-methylenedioxy-amphetamine; | 142 |
| (8) 4-methyl-2,5-dimethoxy-amphetamine (some trade or other | 143 |
| names: 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; "DOM" | 144 |
| and "STP"); | 145 |
| (9) 3,4-methylenedioxy amphetamine (MDA); | 146 |
| (10) 3,4-methylenedioxymethamphetamine (MDMA); | 147 |
| (11) 3,4-methylenedioxy-N-ethylamphetamine (also known as | 148 |
| N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl | 149 |
| MDA, MDE, MDEA); | 150 |
| (12) N-hydroxy-3,4-methylenedioxyamphetamine (also known as | 151 |
| N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine and | 152 |
| N-hydroxy MDA); | 153 |
| (13) 3,4,5-trimethoxy amphetamine; | 154 |
| (14) Bufotenine (some trade or other names: | 155 |
| 3-(beta-dimethylaminoethyl)-5-hydroxyindole; | 156 |
| 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; | 157 |
| 5-hydroxy-N, N-dimethyltryptamine; mappine); | 158 |
| (15) Diethyltryptamine (some trade or other names: N, | 159 |
| N-diethyltryptamine; DET); | 160 |
| (16) Dimethyltryptamine (some trade or other names: DMT); | 161 |
| (17) Ibogaine (some trade or other names: | 162 |
| 7-ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano- | 163 |
| 5H-pyrido[1',2':1,2] azepino [5, 4-b] indole; tabernanthe iboga); | 164 |
| (18) Lysergic acid diethylamide; | 165 |
| (19) Marihuana; | 166 |
| (20) Mescaline; | 167 |
| (21) Parahexyl (some trade or other names: 3-hexyl-1- | 168 |
| hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; | 169 |
| synhexyl); | 170 |
| (22) Peyote (meaning all parts of the plant presently | 171 |
| classified botanically as "Lophophora williamsii Lemaire," whether | 172 |
| growing or not, the seeds of that plant, any extract from any part | 173 |
| of that plant, and every compound, manufacture, salts, derivative, | 174 |
| mixture, or preparation of that plant, its seeds, or its | 175 |
| extracts); | 176 |
| (23) N-ethyl-3-piperidyl benzilate; | 177 |
| (24) N-methyl-3-piperidyl benzilate; | 178 |
| (25) Psilocybin; | 179 |
| (26) Psilocyn; | 180 |
| (27) Tetrahydrocannabinols (synthetic equivalents of the | 181 |
| substances contained in the plant, or in the resinous extractives | 182 |
| of Cannabis, sp. and/or synthetic substances, derivatives, and | 183 |
| their isomers with similar chemical structure and pharmacological | 184 |
| activity such as the following: delta-1-cis or trans | 185 |
| tetrahydrocannabinol, and their optical isomers; delta-6-cis or | 186 |
| trans tetrahydrocannabinol, and their optical isomers; | 187 |
| delta-3,4-cis or trans tetrahydrocannabinol, and its optical | 188 |
| isomers. (Since nomenclature of these substances is not | 189 |
| internationally standardized, compounds of these structures, | 190 |
| regardless of numerical designation of atomic positions, are | 191 |
| covered.)); | 192 |
| (28) Ethylamine analog of phencyclidine (some trade or other | 193 |
| names: N-ethyl-1-phenylcyclohexylamine; | 194 |
| (1-phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; | 195 |
| cyclohexamine; PCE); | 196 |
| (29) Pyrrolidine analog of phencyclidine (some trade or other | 197 |
| names: 1-(1-phenylcyclohexyl)pyrrolidine; PCPy; PHP); | 198 |
| (30) Thiophene analog of phencyclidine (some trade or other | 199 |
| names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; 2-thienyl analog | 200 |
| of phencyclidine; TPCP; TCP); | 201 |
| (31) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine; | 202 |
| (32) Hashish; | 203 |
| (33) Salvia divinorum; | 204 |
| (34) Salvinorin A; | 205 |
| (35) | 206 |
| (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone | 207 |
| (UR-144); | 208 |
| (36) 1-pentyl-3-(1-adamantoyl)indole (AB-001); | 209 |
| (37) N-adamantyl-1-pentylindole-3-carboxamide; | 210 |
| (38) N-adamantyl-1-pentylindazole-3-carboxamide (AKB48); | 211 |
| (39) 2-ethylamino-2-(3-methoxyphenyl)cyclohexanone | 212 |
| (methoxetamine); | 213 |
| (40) N,N-diallyl-5-methoxytryptamine (5MeO-DALT); | 214 |
| (41) | 215 |
| [1-(5-fluoropentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone | 216 |
| (5-fluoropentyl-UR-144; XLR11); | 217 |
| (42) | 218 |
| [1-(5-chloropentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone | 219 |
| (5-chloropentyl-UR-144); | 220 |
| (43) | 221 |
| [1-(5-bromopentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone | 222 |
| (5-bromopentyl-UR-144); | 223 |
| (44) | 224 |
| {1-[2-(4-morpholinyl)ethyl]indol-3-yl}-(2,2,3,3-tetramethylcyclopropyl) | 225 |
| methanone (A-796,260); | 226 |
| (45) | 227 |
| 1-[(N-methylpiperidin-2-yl)methyl]-3-(1-adamantoyl)indole | 228 |
| (AM1248); | 229 |
| (46) N-adamantyl-1-(5-fluoropentylindole)-3-carboxamide; | 230 |
| (47) 5-(2-aminopropyl)benzofuran (5-APB); | 231 |
| (48) 6-(2-aminopropyl)benzofuran (6-APB); | 232 |
| (49) 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB); | 233 |
| (50) 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB); | 234 |
| (51) Benzothiophenylcyclohexylpiperidine (BTCP); | 235 |
| (52) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); | 236 |
| (53) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); | 237 |
| (54) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); | 238 |
| (55) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); | 239 |
| (56) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine | 240 |
| (2C-T-2); | 241 |
| (57) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine | 242 |
| (2C-T-4); | 243 |
| (58) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); | 244 |
| (59) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); | 245 |
| (60) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); | 246 |
| (61) 4-methoxymethamphetamine (PMMA); | 247 |
| (62) 5,6 - Methylenedioxy-2-aminoindane (MDAI); | 248 |
| (63) 5-iodo-2-aminoindiane (5-IAI); | 249 |
| (64) 2-(4-iodo-2,5-dimethoxyphenyl)-N- | 250 |
| [(2-methoxyphenyl)methyl]ethanamine(25I-NBOMe); | 251 |
| (65) Diphenylprolinol (diphenyl(pyrrolidin-2-yl)methanol, | 252 |
| D2PM); | 253 |
| (66) Desoxypipradrol (2-benzhydrylpiperidine); | 254 |
| (67) Synthetic cannabinoids - unless specifically excepted or | 255 |
| unless listed in another schedule, any material, compound, | 256 |
| mixture, or preparation that contains any quantity of a synthetic | 257 |
| cannabinoid found to be in any of the following chemical groups or | 258 |
| any of those groups which contain any synthetic cannabinoid salts, | 259 |
| isomers, or salts of isomers, whenever the existence of such | 260 |
| salts, isomers, or salts of isomers is possible within the | 261 |
| specific chemical groups: | 262 |
| (a) Naphthoylindoles: any compound containing a | 263 |
| 3-(1-naphthoyl)indole structure with or without substitution at | 264 |
| the nitrogen atom of the indole ring by an alkyl, haloalkyl, | 265 |
| alkenyl, cycloalkylmethyl, cycloalkylethyl, | 266 |
| (N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 267 |
| (N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 268 |
| ((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, | 269 |
| whether or not further substituted on the indole ring to any | 270 |
| extent or whether or not substituted on the naphthyl group to any | 271 |
| extent. Naphthoylindoles include, but are not limited to, | 272 |
| 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); | 273 |
| 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201), | 274 |
| 1-pentyl-3-(1-naphthoyl)indole (JWH-018), and | 275 |
| 1-butyl-3-(1-naphthoyl)indole (JWH-073). | 276 |
| (b) Naphthylmethylindoles: any compound containing a | 277 |
| 1H-indol-3-yl-(1-naphthyl)methane structure with or without | 278 |
| substitution at the nitrogen atom of the indole ring by an alkyl, | 279 |
| haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 280 |
| (N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 281 |
| (N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 282 |
| ((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, | 283 |
| whether or not further substituted on the indole ring to any | 284 |
| extent or whether or not substituted on the naphthyl group to any | 285 |
| extent. Naphthylmethylindoles include, but are not limited to, | 286 |
| (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175). | 287 |
| (c) Naphthoylpyrroles: any compound containing a | 288 |
| 3-(1-naphthoyl)pyrrole structure with or without substitution at | 289 |
| the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, | 290 |
| alkenyl, cycloalkylmethyl, cycloalkylethyl, | 291 |
| (N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 292 |
| (N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 293 |
| ((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, | 294 |
| whether or not further substituted on the pyrrole ring to any | 295 |
| extent or whether or not substituted on the naphthyl group to any | 296 |
| extent. Naphthoylpyrroles include, but are not limited to, | 297 |
| 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147). | 298 |
| (d) Naphthylmethylindenes: any compound containing a | 299 |
| naphthylmethylideneindene structure with or without substitution | 300 |
| at the 3-position of the indene ring by an alkyl, haloalkyl, | 301 |
| alkenyl, cycloalkylmethyl, cycloalkylethyl, | 302 |
| (N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 303 |
| (N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 304 |
| ((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, | 305 |
| whether or not further substituted on the indene group to any | 306 |
| extent or whether or not substituted on the naphthyl group to any | 307 |
| extent. Naphthylmethylindenes include, but are not limited to, | 308 |
| (1-[(3-pentyl)-1H-inden-1-ylidene)methyl]naphthalene (JWH-176). | 309 |
| (e) Phenylacetylindoles: any compound containing a | 310 |
| 3-phenylacetylindole structure with or without substitution at the | 311 |
| nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, | 312 |
| cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, | 313 |
| cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, | 314 |
| (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, or | 315 |
| 2-(4-morpholinyl)ethyl group, whether or not further substituted | 316 |
| on the indole ring to any extent or whether or not substituted on | 317 |
| the phenyl group to any extent. Phenylacetylindoles include, but | 318 |
| are not limited to, 1-pentyl-3-(2-methoxyphenylacetyl)indole | 319 |
| (JWH-250), and | 320 |
| 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8); | 321 |
| 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203). | 322 |
| (f) Cyclohexylphenols: any compound containing a | 323 |
| 2-(3-hydroxycyclohexyl)phenol structure with or without | 324 |
| substitution at the 5-position of the phenolic ring by an alkyl, | 325 |
| haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 326 |
| (N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 327 |
| (N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 328 |
| ((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, | 329 |
| whether or not further substituted on the cyclohexyl group to any | 330 |
| extent. Cyclohexylphenols include, but are not limited to, | 331 |
| 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol | 332 |
| (some trade or other names: CP-47,497) and | 333 |
| 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (some | 334 |
| trade or other names: cannabicyclohexanol; CP-47,497 C8 | 335 |
| homologue). | 336 |
| (g) Benzoylindoles: any compound containing a | 337 |
| 3-(1-naphthoyl)indole structure with or without substitution at | 338 |
| the nitrogen atom of the indole ring by an alkyl, haloalkyl, | 339 |
| alkenyl, cycloalkylmethyl, cycloalkylethyl, | 340 |
| (N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 341 |
| (N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 342 |
| ((N-methyl)-3-morpholinyl)methyl or 2-(4-morpholinyl)ethyl group, | 343 |
| whether or not further substituted on the indole ring to any | 344 |
| extent or whether or not substituted on the phenyl group to any | 345 |
| extent. Benzoylindoles include, but are not limited to, | 346 |
| 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4), | 347 |
| 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)indole | 348 |
| (Pravadoline or WIN 48, 098). | 349 |
| (D) Depressants | 350 |
| Any material, compound, mixture, or preparation that contains | 351 |
| any quantity of the following substances having a depressant | 352 |
| effect on the central nervous system, including their salts, | 353 |
| isomers, and salts of isomers, unless specifically excepted under | 354 |
| federal drug abuse control laws, whenever the existence of these | 355 |
| salts, isomers, and salts of isomers is possible within the | 356 |
| specific chemical designation: | 357 |
| (1) Mecloqualone; | 358 |
| (2) Methaqualone. | 359 |
| (E) Stimulants | 360 |
| Unless specifically excepted or unless listed in another | 361 |
| schedule, any material, compound, mixture, or preparation that | 362 |
| contains any quantity of the following substances having a | 363 |
| stimulant effect on the central nervous system, including their | 364 |
| salts, isomers, and salts of isomers: | 365 |
| (1) Aminorex (some other names: aminoxaphen; | 366 |
| 2-amino-5-phenyl-2-oxazoline; or | 367 |
| 4,5-dihydro-5-phenyl-2-oxazolamine); | 368 |
| (2) Fenethylline; | 369 |
| (3) (+/-)cis-4-methylaminorex | 370 |
| ((+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine); | 371 |
| (4) N-ethylamphetamine; | 372 |
| (5) N,N-dimethylamphetamine (also known as | 373 |
| N,N-alpha-trimethyl-benzeneethanamine; | 374 |
| N,N-alpha-trimethylphenethylamine); | 375 |
| (6) N-methyl-1-(thiophen-2-yl) propan-2-amine | 376 |
| (Methiopropamine); | 377 |
| (7) Substituted cathinones - any compound except bupropion or | 378 |
| compounds listed under a different schedule, structurally derived | 379 |
| from 2-aminopropan-1-one by substitution at the 1-position with | 380 |
| either phenyl, naphthyl, or thiophene ring systems, whether or not | 381 |
| the compound is further modified in any of the following ways: | 382 |
| (a) By substitution in the ring system to any extent with | 383 |
| alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide | 384 |
| substituents, whether or not further substituted in the ring | 385 |
| system by one or more other univalent substituents; | 386 |
| (b) By substitution at the 3-position with an acyclic alkyl | 387 |
| substituent; | 388 |
| (c) By substitution at the 2-amino nitrogen atom with alkyl, | 389 |
| dialkyl, benzyl, or methoxybenzyl groups; | 390 |
| (d) By inclusion of the 2-amino nitrogen atom in a cyclic | 391 |
| structure. | 392 |
| Examples of substituted cathinones include, but are not | 393 |
| limited to, methylone (3,4-methylenedioxymethcathinone), MDPV | 394 |
| (3,4-methylenedioxypyrovalerone), mephedrone | 395 |
| (4-methylmethcathinone), 4-methoxymethcathinone, | 396 |
| 4-fluoromethcathinone, 3-fluoromethcathinone, Pentedrone | 397 |
| (2-(methylamino)-1-phenyl-1-pentanone), pentylone | 398 |
| (1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-pentanone), | 399 |
| 2-(1-pyrrolidinyl)-1-(4-methylphenyl)-1-propanone, alpha-PVP | 400 |
| (1-phenyl-2-(1-pyrrodinyl)-1-pentanone), cathinone | 401 |
| (2-amino-1-phenyl-1-propanone), and methcathinone | 402 |
| (2-(methylamino)-propiophenone). | 403 |
| 404 | |
| (A) Narcotics-opium and opium derivatives | 405 |
| Unless specifically excepted under federal drug abuse control | 406 |
| laws or unless listed in another schedule, any of the following | 407 |
| substances whether produced directly or indirectly by extraction | 408 |
| from substances of vegetable origin, independently by means of | 409 |
| chemical synthesis, or by a combination of extraction and chemical | 410 |
| synthesis: | 411 |
| (1) Opium and opiate, and any salt, compound, derivative, or | 412 |
| preparation of opium or opiate, excluding apomorphine, | 413 |
| thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, | 414 |
| naloxone, and naltrexone, and their respective salts, but | 415 |
| including the following: | 416 |
| (a) Raw opium; | 417 |
| (b) Opium extracts; | 418 |
| (c) Opium fluid extracts; | 419 |
| (d) Powdered opium; | 420 |
| (e) Granulated opium; | 421 |
| (f) Tincture of opium; | 422 |
| (g) Codeine; | 423 |
| (h) Ethylmorphine; | 424 |
| (i) Etorphine hydrochloride; | 425 |
| (j) Hydrocodone; | 426 |
| (k) Hydromorphone; | 427 |
| (l) Metopon; | 428 |
| (m) Morphine; | 429 |
| (n) Oxycodone; | 430 |
| (o) Oxymorphone; | 431 |
| (p) Thebaine. | 432 |
| (2) Any salt, compound, derivative, or preparation thereof | 433 |
| that is chemically equivalent to or identical with any of the | 434 |
| substances referred to in division (A)(1) of this schedule, except | 435 |
| that these substances shall not include the isoquinoline alkaloids | 436 |
| of opium; | 437 |
| (3) Opium poppy and poppy straw; | 438 |
| (4) Coca leaves and any salt, compound, derivative, or | 439 |
| preparation of coca leaves (including cocaine and ecgonine, their | 440 |
| salts, isomers, and derivatives, and salts of those isomers and | 441 |
| derivatives), and any salt, compound, derivative, or preparation | 442 |
| thereof that is chemically equivalent to or identical with any of | 443 |
| these substances, except that the substances shall not include | 444 |
| decocainized coca leaves or extraction of coca leaves, which | 445 |
| extractions do not contain cocaine or ecgonine; | 446 |
| (5) Concentrate of poppy straw (the crude extract of poppy | 447 |
| straw in either liquid, solid, or powder form that contains the | 448 |
| phenanthrene alkaloids of the opium poppy). | 449 |
| (B) Narcotics-opiates | 450 |
| Unless specifically excepted under federal drug abuse control | 451 |
| laws or unless listed in another schedule, any of the following | 452 |
| opiates, including their isomers, esters, ethers, salts, and salts | 453 |
| of isomers, esters, and ethers, whenever the existence of these | 454 |
| isomers, esters, ethers, and salts is possible within the specific | 455 |
| chemical designation, but excluding dextrorphan and | 456 |
| levopropoxyphene: | 457 |
| (1) Alfentanil; | 458 |
| (2) Alphaprodine; | 459 |
| (3) Anileridine; | 460 |
| (4) Bezitramide; | 461 |
| (5) Bulk dextropropoxyphene (non-dosage forms); | 462 |
| (6) Carfentanil; | 463 |
| (7) Dihydrocodeine; | 464 |
| (8) Diphenoxylate; | 465 |
| (9) Fentanyl; | 466 |
| (10) Isomethadone; | 467 |
| (11) Levo-alphacetylmethadol (some other names: | 468 |
| levo-alpha-acetylmethadol; levomethadyl acetate; LAAM); | 469 |
| (12) Levomethorphan; | 470 |
| (13) Levorphanol; | 471 |
| (14) Metazocine; | 472 |
| (15) Methadone; | 473 |
| (16) Methadone-intermediate, | 474 |
| 4-cyano-2-dimethylamino-4,4-diphenyl butane; | 475 |
| (17) Moramide-intermediate, | 476 |
| 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid; | 477 |
| (18) Pethidine (meperidine); | 478 |
| (19) Pethidine-intermediate-A, | 479 |
| 4-cyano-1-methyl-4-phenylpiperidine; | 480 |
| (20) Pethidine-intermediate-B, | 481 |
| ethyl-4-phenylpiperidine-4-carboxylate; | 482 |
| (21) Pethidine-intermediate-C, | 483 |
| 1-methyl-4-phenylpiperidine-4-carboxylic acid; | 484 |
| (22) Phenazocine; | 485 |
| (23) Piminodine; | 486 |
| (24) Racemethorphan; | 487 |
| (25) Racemorphan; | 488 |
| (26) Remifentanil; | 489 |
| (27) Sufentanil. | 490 |
| (C) Stimulants | 491 |
| Unless specifically excepted under federal drug abuse control | 492 |
| laws or unless listed in another schedule, any material, compound, | 493 |
| mixture, or preparation that contains any quantity of the | 494 |
| following substances having a stimulant effect on the central | 495 |
| nervous system: | 496 |
| (1) Amphetamine, its salts, its optical isomers, and salts of | 497 |
| its optical isomers; | 498 |
| (2) Methamphetamine, its salts, its isomers, and salts of its | 499 |
| isomers; | 500 |
| (3) Methylphenidate; | 501 |
| (4) Phenmetrazine and its salts. | 502 |
| (D) Depressants | 503 |
| Unless specifically excepted under federal drug abuse control | 504 |
| laws or unless listed in another schedule, any material, compound, | 505 |
| mixture, or preparation that contains any quantity of the | 506 |
| following substances having a depressant effect on the central | 507 |
| nervous system, including their salts, isomers, and salts of | 508 |
| isomers, whenever the existence of these salts, isomers, and salts | 509 |
| of isomers is possible within the specific chemical designation: | 510 |
| (1) Amobarbital; | 511 |
| (2) Gamma-hydroxy-butyrate; | 512 |
| (3) Glutethimide; | 513 |
| (4) Pentobarbital; | 514 |
| (5) Phencyclidine (some trade or other names: | 515 |
| 1-(1-phenylcyclohexyl)piperidine; PCP); | 516 |
| (6) Secobarbital; | 517 |
| (7) 1-aminophenylcyclohexane and all N-mono-substituted | 518 |
| and/or all N-N-disubstituted analogs including, but not limited | 519 |
| to, the following: | 520 |
| (a) 1-phenylcyclohexylamine; | 521 |
| (b) (1-phenylcyclohexyl) methylamine; | 522 |
| (c) (1-phenylcyclohexyl) dimethylamine; | 523 |
| (d) (1-phenylcyclohexyl) methylethylamine; | 524 |
| (e) (1-phenylcyclohexyl) isopropylamine; | 525 |
| (f) 1-(1-phenylcyclohexyl) morpholine. | 526 |
| (E) Hallucinogenic substances | 527 |
| (1) Nabilone (another name for nabilone: | 528 |
| (+)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1- | 529 |
| hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one). | 530 |
| (F) Immediate precursors | 531 |
| Unless specifically excepted under federal drug abuse control | 532 |
| laws or unless listed in another schedule, any material, compound, | 533 |
| mixture, or preparation that contains any quantity of the | 534 |
| following substances: | 535 |
| (1) Immediate precursor to amphetamine and methamphetamine: | 536 |
| (a) Phenylacetone (some trade or other names: | 537 |
| phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl | 538 |
| ketone); | 539 |
| (2) Immediate precursors to phencyclidine (PCP): | 540 |
| (a) 1-phenylcyclohexylamine; | 541 |
| (b) 1-piperidinocyclohexanecarbonitrile (PCC). | 542 |
| 543 | |
| (A) Stimulants | 544 |
| Unless specifically excepted under federal drug abuse control | 545 |
| laws or unless listed in another schedule, any material, compound, | 546 |
| mixture, or preparation that contains any quantity of the | 547 |
| following substances having a stimulant effect on the central | 548 |
| nervous system, including their salts, their optical isomers, | 549 |
| position isomers, or geometric isomers, and salts of these | 550 |
| isomers, whenever the existence of these salts, isomers, and salts | 551 |
| of isomers is possible within the specific chemical designation: | 552 |
| (1) All stimulant compounds, mixtures, and preparations | 553 |
| included in schedule III pursuant to the federal drug abuse | 554 |
| control laws and regulations adopted under those laws; | 555 |
| (2) Benzphetamine; | 556 |
| (3) Chlorphentermine; | 557 |
| (4) Clortermine; | 558 |
| (5) Phendimetrazine. | 559 |
| (B) Depressants | 560 |
| Unless specifically excepted under federal drug abuse control | 561 |
| laws or unless listed in another schedule, any material, compound, | 562 |
| mixture, or preparation that contains any quantity of the | 563 |
| following substances having a depressant effect on the central | 564 |
| nervous system: | 565 |
| (1) Any compound, mixture, or preparation containing | 566 |
| amobarbital, secobarbital, pentobarbital, or any salt of any of | 567 |
| these drugs, and one or more other active medicinal ingredients | 568 |
| that are not listed in any schedule; | 569 |
| (2) Any suppository dosage form containing amobarbital, | 570 |
| secobarbital, pentobarbital, or any salt of any of these drugs and | 571 |
| approved by the food and drug administration for marketing only as | 572 |
| a suppository; | 573 |
| (3) Any substance that contains any quantity of a derivative | 574 |
| of barbituric acid or any salt of a derivative of barbituric acid; | 575 |
| (4) Chlorhexadol; | 576 |
| (5) Ketamine, its salts, isomers, and salts of isomers (some | 577 |
| other names for ketamine: | 578 |
| (+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone); | 579 |
| (6) Lysergic acid; | 580 |
| (7) Lysergic acid amide; | 581 |
| (8) Methyprylon; | 582 |
| (9) Sulfondiethylmethane; | 583 |
| (10) Sulfonethylmethane; | 584 |
| (11) Sulfonmethane; | 585 |
| (12) Tiletamine, zolazepam, or any salt of tiletamine or | 586 |
| zolazepam (some trade or other names for a tiletamine-zolazepam | 587 |
| combination product: Telazol); (some trade or other names for | 588 |
| tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone); (some | 589 |
| trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8- | 590 |
| dihydro-1,3,8-trimethylpyrazolo-[3, 4-e][1,4]-diazepin-7(1H)-one; | 591 |
| flupyrazapon). | 592 |
| (C) Narcotic antidotes | 593 |
| (1) Nalorphine. | 594 |
| (D) Narcotics-narcotic preparations | 595 |
| Unless specifically excepted under federal drug abuse control | 596 |
| laws or unless listed in another schedule, any material, compound, | 597 |
| mixture, or preparation that contains any of the following | 598 |
| narcotic drugs, or their salts calculated as the free anhydrous | 599 |
| base or alkaloid, in limited quantities as set forth below: | 600 |
| (1) Not more than 1.8 grams of codeine per 100 milliliters or | 601 |
| not more than 90 milligrams per dosage unit, with an equal or | 602 |
| greater quantity of an isoquinoline alkaloid of opium; | 603 |
| (2) Not more than 1.8 grams of codeine per 100 milliliters or | 604 |
| not more than 90 milligrams per dosage unit, with one or more | 605 |
| active, nonnarcotic ingredients in recognized therapeutic amounts; | 606 |
| (3) Not more than 300 milligrams of dihydrocodeinone per 100 | 607 |
| milliliters or not more than 15 milligrams per dosage unit, with a | 608 |
| fourfold or greater quantity of an isoquinoline alkaloid of opium; | 609 |
| (4) Not more than 300 milligrams of dihydrocodeinone per 100 | 610 |
| milliliters or not more than 15 milligrams per dosage unit, with | 611 |
| one or more active, nonnarcotic ingredients in recognized | 612 |
| therapeutic amounts; | 613 |
| (5) Not more than 1.8 grams of dihydrocodeine per 100 | 614 |
| milliliters or not more than 90 milligrams per dosage unit, with | 615 |
| one or more active, nonnarcotic ingredients in recognized | 616 |
| therapeutic amounts; | 617 |
| (6) Not more than 300 milligrams of ethylmorphine per 100 | 618 |
| milliliters or not more than 15 milligrams per dosage unit, with | 619 |
| one or more active, nonnarcotic ingredients in recognized | 620 |
| therapeutic amounts; | 621 |
| (7) Not more than 500 milligrams of opium per 100 milliliters | 622 |
| or per 100 grams or not more than 25 milligrams per dosage unit, | 623 |
| with one or more active, nonnarcotic ingredients in recognized | 624 |
| therapeutic amounts; | 625 |
| (8) Not more than 50 milligrams of morphine per 100 | 626 |
| milliliters or per 100 grams, with one or more active, nonnarcotic | 627 |
| ingredients in recognized therapeutic amounts. | 628 |
| (E) Anabolic steroids | 629 |
| Unless specifically excepted under federal drug abuse control | 630 |
| laws or unless listed in another schedule, any material, compound, | 631 |
| mixture, or preparation that contains any quantity of the | 632 |
| following substances, including their salts, esters, isomers, and | 633 |
| salts of esters and isomers, whenever the existence of these | 634 |
| salts, esters, and isomers is possible within the specific | 635 |
| chemical designation: | 636 |
| (1) Anabolic steroids. Except as otherwise provided in | 637 |
| division (E)(1) of schedule III, "anabolic steroids" means any | 638 |
| drug or hormonal substance that is chemically and | 639 |
| pharmacologically related to testosterone (other than estrogens, | 640 |
| progestins, and corticosteroids) and that promotes muscle growth. | 641 |
| "Anabolic steroids" does not include an anabolic steroid that is | 642 |
| expressly intended for administration through implants to cattle | 643 |
| or other nonhuman species and that has been approved by the United | 644 |
| States secretary of health and human services for that | 645 |
| administration, unless a person prescribes, dispenses, or | 646 |
| distributes this type of anabolic steroid for human use. "Anabolic | 647 |
| steroid" includes, but is not limited to, the following: | 648 |
| (a) Boldenone; | 649 |
| (b) Chlorotestosterone (4-chlortestosterone); | 650 |
| (c) Clostebol; | 651 |
| (d) Dehydrochlormethyltestosterone; | 652 |
| (e) Dihydrotestosterone (4-dihydrotestosterone); | 653 |
| (f) Drostanolone; | 654 |
| (g) Ethylestrenol; | 655 |
| (h) Fluoxymesterone; | 656 |
| (i) Formebulone (formebolone); | 657 |
| (j) Mesterolone; | 658 |
| (k) Methandienone; | 659 |
| (l) Methandranone; | 660 |
| (m) Methandriol; | 661 |
| (n) Methandrostenolone; | 662 |
| (o) Methenolone; | 663 |
| (p) Methyltestosterone; | 664 |
| (q) Mibolerone; | 665 |
| (r) Nandrolone; | 666 |
| (s) Norethandrolone; | 667 |
| (t) Oxandrolone; | 668 |
| (u) Oxymesterone; | 669 |
| (v) Oxymetholone; | 670 |
| (w) Stanolone; | 671 |
| (x) Stanozolol; | 672 |
| (y) Testolactone; | 673 |
| (z) Testosterone; | 674 |
| (aa) Trenbolone; | 675 |
| (bb) Any salt, ester, isomer, or salt of an ester or isomer | 676 |
| of a drug or hormonal substance described or listed in division | 677 |
| (E)(1) of schedule III if the salt, ester, or isomer promotes | 678 |
| muscle growth. | 679 |
| (F) Hallucinogenic substances | 680 |
| (1) Dronabinol (synthetic) in sesame oil and encapsulated in | 681 |
| a soft gelatin capsule in a United States food and drug | 682 |
| administration approved drug product (some other names for | 683 |
| dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- | 684 |
| 6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or | 685 |
| (-)-delta-9-(trans)-tetrahydrocannabinol). | 686 |
| 687 | |
| (A) Narcotic drugs | 688 |
| Unless specifically excepted by federal drug abuse control | 689 |
| laws or unless listed in another schedule, any material, compound, | 690 |
| mixture, or preparation that contains any of the following | 691 |
| narcotic drugs, or their salts calculated as the free anhydrous | 692 |
| base or alkaloid, in limited quantities as set forth below: | 693 |
| (1) Not more than one milligram of difenoxin and not less | 694 |
| than 25 micrograms of atropine sulfate per dosage unit; | 695 |
| (2) Dextropropoxyphene | 696 |
| (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- | 697 |
| propionoxybutane)[final dosage forms]. | 698 |
| (B) Depressants | 699 |
| Unless specifically excepted under federal drug abuse control | 700 |
| laws or unless listed in another schedule, any material, compound, | 701 |
| mixture, or preparation that contains any quantity of the | 702 |
| following substances, including their salts, isomers, and salts of | 703 |
| isomers, whenever the existence of these salts, isomers, and salts | 704 |
| of isomers is possible within the specific chemical designation: | 705 |
| (1) Alprazolam; | 706 |
| (2) Barbital; | 707 |
| (3) Bromazepam; | 708 |
| (4) Camazepam; | 709 |
| (5) Chloral betaine; | 710 |
| (6) Chloral hydrate; | 711 |
| (7) Chlordiazepoxide; | 712 |
| (8) Clobazam; | 713 |
| (9) Clonazepam; | 714 |
| (10) Clorazepate; | 715 |
| (11) Clotiazepam; | 716 |
| (12) Cloxazolam; | 717 |
| (13) Delorazepam; | 718 |
| (14) Diazepam; | 719 |
| (15) Estazolam; | 720 |
| (16) Ethchlorvynol; | 721 |
| (17) Ethinamate; | 722 |
| (18) Ethyl loflazepate; | 723 |
| (19) Fludiazepam; | 724 |
| (20) Flunitrazepam; | 725 |
| (21) Flurazepam; | 726 |
| (22) Halazepam; | 727 |
| (23) Haloxazolam; | 728 |
| (24) Ketazolam; | 729 |
| (25) Loprazolam; | 730 |
| (26) Lorazepam; | 731 |
| (27) Lormetazepam; | 732 |
| (28) Mebutamate; | 733 |
| (29) Medazepam; | 734 |
| (30) Meprobamate; | 735 |
| (31) Methohexital; | 736 |
| (32) Methylphenobarbital (mephobarbital); | 737 |
| (33) Midazolam; | 738 |
| (34) Nimetazepam; | 739 |
| (35) Nitrazepam; | 740 |
| (36) Nordiazepam; | 741 |
| (37) Oxazepam; | 742 |
| (38) Oxazolam; | 743 |
| (39) Paraldehyde; | 744 |
| (40) Petrichloral; | 745 |
| (41) Phenobarbital; | 746 |
| (42) Pinazepam; | 747 |
| (43) Prazepam; | 748 |
| (44) Quazepam; | 749 |
| (45) Temazepam; | 750 |
| (46) Tetrazepam; | 751 |
| (47) Triazolam; | 752 |
| (48) Zaleplon; | 753 |
| (49) Zolpidem. | 754 |
| (C) Fenfluramine | 755 |
| Any material, compound, mixture, or preparation that contains | 756 |
| any quantity of the following substances, including their salts, | 757 |
| their optical isomers, position isomers, or geometric isomers, and | 758 |
| salts of these isomers, whenever the existence of these salts, | 759 |
| isomers, and salts of isomers is possible within the specific | 760 |
| chemical designation: | 761 |
| (1) Fenfluramine. | 762 |
| (D) Stimulants | 763 |
| Unless specifically excepted under federal drug abuse control | 764 |
| laws or unless listed in another schedule, any material, compound, | 765 |
| mixture, or preparation that contains any quantity of the | 766 |
| following substances having a stimulant effect on the central | 767 |
| nervous system, including their salts, their optical isomers, | 768 |
| position isomers, or geometric isomers, and salts of these | 769 |
| isomers, whenever the existence of these salts, isomers, and salts | 770 |
| of isomers is possible within the specific chemical designation: | 771 |
| (1) Cathine ((+)-norpseudoephedrine); | 772 |
| (2) Diethylpropion; | 773 |
| (3) Fencamfamin; | 774 |
| (4) Fenproporex; | 775 |
| (5) Mazindol; | 776 |
| (6) Mefenorex; | 777 |
| (7) Modafinil; | 778 |
| (8) Pemoline (including organometallic complexes and chelates | 779 |
| thereof); | 780 |
| (9) Phentermine; | 781 |
| (10) Pipradrol; | 782 |
| (11) Sibutramine; | 783 |
| (12) SPA [(-)-1-dimethylamino-1,2-diphenylethane]. | 784 |
| (E) Other substances | 785 |
| Unless specifically excepted under federal drug abuse control | 786 |
| laws or unless listed in another schedule, any material, compound, | 787 |
| mixture, or preparation that contains any quantity of the | 788 |
| following substances, including their salts: | 789 |
| (1) Pentazocine; | 790 |
| (2) Butorphanol (including its optical isomers). | 791 |
| 792 | |
| (A) Narcotic drugs | 793 |
| Unless specifically excepted under federal drug abuse control | 794 |
| laws or unless listed in another schedule, any material, compound, | 795 |
| mixture, or preparation that contains any of the following | 796 |
| narcotic drugs, and their salts, as set forth below: | 797 |
| (1) Buprenorphine. | 798 |
| (B) Narcotics-narcotic preparations | 799 |
| Narcotic drugs containing non-narcotic active medicinal | 800 |
| ingredients. Any compound, mixture, or preparation that contains | 801 |
| any of the following narcotic drugs, or their salts calculated as | 802 |
| the free anhydrous base or alkaloid, in limited quantities as set | 803 |
| forth below, and that includes one or more nonnarcotic active | 804 |
| medicinal ingredients in sufficient proportion to confer upon the | 805 |
| compound, mixture, or preparation valuable medicinal qualities | 806 |
| other than those possessed by narcotic drugs alone: | 807 |
| (1) Not more than 200 milligrams of codeine per 100 | 808 |
| milliliters or per 100 grams; | 809 |
| (2) Not more than 100 milligrams of dihydrocodeine per 100 | 810 |
| milliliters or per 100 grams; | 811 |
| (3) Not more than 100 milligrams of ethylmorphine per 100 | 812 |
| milliliters or per 100 grams; | 813 |
| (4) Not more than 2.5 milligrams of diphenoxylate and not | 814 |
| less than 25 micrograms of atropine sulfate per dosage unit; | 815 |
| (5) Not more than 100 milligrams of opium per 100 milliliters | 816 |
| or per 100 grams; | 817 |
| (6) Not more than 0.5 milligram of difenoxin and not less | 818 |
| than 25 micrograms of atropine sulfate per dosage unit. | 819 |
| (C) Stimulants | 820 |
| Unless specifically exempted or excluded under federal drug | 821 |
| abuse control laws or unless listed in another schedule, any | 822 |
| material, compound, mixture, or preparation that contains any | 823 |
| quantity of the following substances having a stimulant effect on | 824 |
| the central nervous system, including their salts, isomers, and | 825 |
| salts of isomers: | 826 |
| (1) Ephedrine, except as provided in division (K) of section | 827 |
| 3719.44 of the Revised Code; | 828 |
| (2) Pyrovalerone. | 829 |
| Section 2. That existing section 3719.41 of the Revised Code | 830 |
| is hereby repealed. | 831 |
